Comparative Stroke, Bleeding, and Mortality

ARTICLE IN PRESS Supplementary Figure 2 Hazard ratios (95% confidence intervals) for thromboembolic stroke, intracranial hemorrhage, major extracranial bleeding, and all-cause mortality from sensitivity analyses in elderly patients treated with warfarin, dabigatran, rivaroxaban, or apixaban for nonvalvular atrial fibrillation. The conditions covered by the sensitivity analyses included using a 14-day gap allowance, restriction to patients who initiated anticoagulant therapy after the approval date for apixaban, restriction to patients who received 2 or more study drug prescriptions, multivariable Cox regression, and a crude (unadjusted) analysis. (A) Each nonvitamin K antagonist oral anticoagulant (NOAC) vs warfarin. (B) NOAC vs NOAC. Graham et al Comparative Safety and Effectiveness of Anticoagulants in Atrial Fibrillation 9.e8